ECDC, DG SANTE and EFSA, supported by a consortium composed of Epiconcept and Integrated Quality Laboratory Services (IQLS), jointly carried out a country visit to Kosovo* from 9 to 13 October 2023, which is part of ECDC’s accession support activities to contribute to the advancement of a One Health approach against antimicrobial resistance (AMR) in the Western Balkans.
This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 August 2023 until 31 January 2024.
The 2022–2023 ECDC PPS was the third EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This report presents surveillance data on Clostridioides (Clostridium) difficile infection (CDI) in acute care hospitals in European Union/European Economic Area (EU/EEA) countries, the UK, and Serbia.
The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.
In 2022, 23 273 cases of hepatitis C were reported in 29 EU/EEA countries. Excluding countries that only reported acute cases, 23 249 cases were notified, corresponding to a crude rate of 6.2 cases per 100 000 population.
This global technical consultation report brings together viewpoints from experts spanning a range of disciplines with the key objective of seeking consensus regarding the terminology used to describe the transmission of pathogens through the air that can potentially cause infection in humans.
This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
A cross-border outbreak of Salmonella Mbandaka ST413 has been ongoing in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) for over two years since September 2021.